These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17219666)

  • 21. Failure of combination abacavir + tenofovir + lamivudine (3TC).
    AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM; d'Ettorre G; Vullo V
    Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
    d'Ettorre G; Mastroianni CM; Massetti AP; Lichtner M; D'Agostino C; Vullo V
    AIDS; 2005 May; 19(8):841-2. PubMed ID: 15867503
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of gender and anchor drugs on TDF renal toxicity.
    Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
    [No Abstract]   [Full Text] [Related]  

  • 25. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
    Mauss S; Milinkovic A; Hoffmann C; Holm S; Berger F; Martínez E; Kuhlmann B; Gatell J; Schmutz G
    AIDS; 2005 Jan; 19(1):101-2. PubMed ID: 15627042
    [No Abstract]   [Full Text] [Related]  

  • 26. Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
    Quercia R; Amiel C; Marechal Eda S; Lebrette MG; Thevenet S; Renaud S; Schneider V; Kara A; Guessant S; Pialoux G
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):389-90. PubMed ID: 16763531
    [No Abstract]   [Full Text] [Related]  

  • 27. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
    Becker S; Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 30. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 32. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 33. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
    Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
    PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
    Khanlou H; Yeh V; Guyer B; Farthing C
    AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
    Lyagoba F; Dunn DT; Pillay D; Kityo C; Robertson V; Tugume S; Hakim J; Munderi P; Chirara M; Ndembi N; Goodall RL; Yirrell DL; Burke A; Gilks CF; Kaleebu P;
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):277-83. PubMed ID: 20686411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
    Ross LL; Rouse E; Gerondelis P; DeJesus E; Cohen C; Horton J; Ha B; Lanier ER; Elion R;
    J Antimicrob Chemother; 2010 Feb; 65(2):307-15. PubMed ID: 20008905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.